Having trouble accessing articles? Reset your cache.

IPI-145: Phase II started

Infinity disclosed in its 1Q13 earnings that it began the double-blind, placebo-controlled Phase II ASPIRA

Read the full 151 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE